TLV has decided to reconsider the subsidy status for certain drugs

26 May 2020 - TLV initiates a review for review of subsidy status for drugs that are part of one ...

Read more →

Half yearly performance snapshot: July to December 2019

6 May 2020 - The TGA prepares an annual TGA Business Plan, which identifies the priority activities being undertaken over the ...

Read more →

EMA starts rolling review of remdesivir for COVID-19

30 April 2020 - EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on the use of ...

Read more →

Pharmacists welcome medicine review update

21 April 2020 - Elderly people at risk of medicine-related harm will now have their treatments more regularly reviewed by ...

Read more →

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

13 April 2020 - The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 ...

Read more →

The review shows that it is possible to lower the cost of medicines

3 April 2020 - There are opportunities to make savings on medicines.  ...

Read more →

Independent review of the reforms to the therapeutic goods advertising framework to commence

26 February 2020 - The independent review of the advertising reforms has now commenced, and is being led by Ms Rosemary ...

Read more →

Serving public health paramount in a successful 2019 for FDA’s generic drug program

19 February 2020 - Safe, effective, high-quality generic drugs play a vital role in the U.S. health care system.  ...

Read more →

TLV is reviewing the subsidy of factor VIII drugs with side agreements

28 January 2020 - Factor VIII drugs are used to treat a form of hemorrhagic disease, hemophilia A, which involves ...

Read more →

Reform at the FDA—in need of reform

14 January 2020 - On 23 December 2016, the US FDA announced the approval of nusinersen, the first drug for the ...

Read more →

TLV has decided to reconsider the subsidy for Xeljanz

14 January 2020 - When TLV decided that Xeljanz should be included in the high-cost protection, this was justified by the ...

Read more →

Human medicines: highlights of 2019

9 January 2020 - EMA has published a review of its key recommendations in 2019 on the authorisation and safety ...

Read more →

PBAC – 2019 in review

8 January 2020 - The PBAC considered 188 submissions in 2019. ...

Read more →

Novel drug approvals for 2019

2 January 2020 - How many of the 'novel' drugs approved by the FDA in 2019 are actually new medicines in ...

Read more →

The use of risk-sharing contracts in health care: theoretical and empirical assessments

3 December 2019 - The aim of this review is to provide a summary of the literature on risk-sharing agreements, including ...

Read more →